New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 5, 2014
07:55 EDTATRS, ATRS, BDX, BDX, ANTH, ANTH, NKTR, NKTR, SSH, SSH, IDRA, IDRA, LXRX, LXRX, ARAY, ARAY, ABBV, ABBV, INFI, INFI, JAZZ, JAZZ, IMMU, IMMUCowen to host a conference
34th Annual Global Healthcare Conference is being held in Boston on March 3-5 with webcasted company presentations to begin on March 5 at 8:00 am; not all company presentations may be webcasted. Webcast Link
News For ATRS;JAZZ;INFI;ABBV;ARAY;LXRX;IDRA;SSH;NKTR;ANTH;BDX;IMMU From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 >>
February 10, 2016
08:24 EDTNKTREnzon says Nektar granted motion to dismiss breach of contract complaint
Subscribe for More Information
07:02 EDTBDXBecton Dickinson receives FDA 510(k) clearance for HIV/AIDS diagnostic device
BD has received FDA 510(k) clearance for its BD FACSPresto system and BD FACSPresto CD4/Hb Cartridge. The BD FACSPresto system is an automated multicolor fluorescent imaging cytometer and absorbance spectrometer that provides absolute and percentage results of CD4 T lymphocytes and hemoglobin concentration in whole blood samples to manage HIV/AIDS patients.
06:58 EDTABBVAbbVie reports second Elagolix Phase 3 clinical trial met co-primary endpoint
AbbVie (ABBV), in cooperation with Neurocrine Biosciences (NBIX), announced positive top-line results from the second of two replicate pivotal Phase 3 clinical trials evaluating the efficacy and safety of Elagolix in premenopausal women who suffer pain from endometriosis. Trial results show that after six months of continuous treatment, both doses of Elagolix met the study's co-primary endpoints. Elagolix reduced scores of menstrual pain and non-menstrual pelvic pain, or NMPP, associated with endometriosis, at month three and month six, as measured by the Daily Assessment of Endometriosis Pain scale. Responder rates for the co-primary endpoints from this second Phase 3 pivotal study are consistent with results from the first Phase 3 pivotal study.
February 8, 2016
16:06 EDTABBVEnanta sees Q2 royalty revenue at least 3% of AbbVie's reported VIEKIRA sales
Subscribe for More Information
February 7, 2016
14:30 EDTABBVAbbVie's juvenile arthritis treatment receives orphan designation
Subscribe for More Information
14:10 EDTABBVAbbVie's venetoclax receives orphan designation for myeloid leukemia
Subscribe for More Information
February 5, 2016
12:33 EDTIMMUImmunomedics upgraded to Outperform from Market Perform at Wells Fargo
Subscribe for More Information
10:02 EDTABBVOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: 21st Century Fox (FOXA) initiated with an Outperform at Telsey Advisory... AbbVie (ABBV) initiated with an Outperform at William Blair... CBS (CBS) initiated with an Outperform at Telsey Advisory... Criteo (CRTO) initiated with an Outperform at Boenning & Scattergood... LHC Group (LHCG) initiated with a Buy at Jefferies... Marriott Vacations (VAC) initiated with an Outperform at Credit Suisse... Prestige Brands (PBH) initiated with an Overweight at Piper Jaffray... Rubicon Project (RUBI) initiated with an Outperform at Boenning & Scattergood... TESARO (TSRO) initiated with a Buy at Lake Street... Time Warner (TWX) initiated with an Outperform at Telsey Advisory... TubeMogul (TUBE) initiated with a Neutral at Boenning & Scattergood... Viacom (VIAB) initiated with an Outperform at Telsey Advisory... Wyndham (WYN) initiated with a Neutral at Credit Suisse.
09:37 EDTABBVActive equity options trading on open
Subscribe for More Information
09:32 EDTIMMUImmunomedics granted breakthrough therapy designation for sacituzumab govitecan
Immunomedics announced that its lead investigational antibody-drug conjugate, sacituzumab govitecan, or IMMU-132, has received Breakthrough Therapy Designation from the FDA for the treatment of patients with triple-negative breast cancer who have failed at least 2 prior therapies for metastatic disease.
09:29 EDTIMMUImmunomedics granted Breakthrough Therapy Designation from FDA for IMMU-132
Subscribe for More Information
06:28 EDTABBVAbbVie initiated with an Outperform at William Blair
William Blair analyst Y. Katherine Xu started AbbVie with an Outperform rating and $76 price target. The Humira franchise has "higher and longer growth prospects" than the Street projects, Xu tells investors in a research note.
February 4, 2016
12:41 EDTABBVAbbVie management to meet with Evercore ISI
Subscribe for More Information
February 3, 2016
16:05 EDTIMMUImmunomedics sees Phase 3 PANCRIT-1 trial completing enrollment in 2016
Subscribe for More Information
16:03 EDTIMMUImmunomedics reports Q2 EPS (15c), two estimates (14c)
Subscribe for More Information
06:14 EDTBDXBecton Dickinson backs FY16 adjusted EPS view of $8.37-$8.44, consensus $8.41
Subscribe for More Information
06:08 EDTBDXBecton Dickinson reports Q1 adjusted EPS $1.96, consensus $1.84
Reports Q1 revenue $2.99B, consensus $3.03B.
February 2, 2016
14:32 EDTBDXNotable companies reporting before tomorrow's open
Subscribe for More Information
February 1, 2016
09:08 EDTJAZZJazz Pharmaceuticals reports data from Phase 3 pivotal study of defibrotide
Jazz Pharmaceuticals announced that data from the phase 3 pivotal study of defibrotide were published online in BLOOD, the Journal of the American Society of Hematology, or ASH. The data demonstrated that defibrotide use in patients with hepatic veno-occlusive, or VOD, also known as sinusoidal obstruction syndrome, with multi-organ failure post-hematopoietic stem-cell transplantation was associated with a statistically significant improvement in Day +100 survival and in rate of complete response by Day +100, compared with rigorously selected historical controls.
09:02 EDTNKTRNektar announces publication of findings for NKTR-214
Subscribe for More Information
1 | 2 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use